Search

A recent study conducted at Tripler Army Medical Center in Honolulu, Hawaii, focused on primary mediastinal large B-cell lymphoma (PMBCL) in a 23-year-old male sailor. The research highlighted the challenges in diagnosing and treating PMBCL, emphasizing the importance of recognizing mediastinal masses in young adults, particularly in the military population. The case study underscored the need for prompt and specialized care to prevent life-threatening complications in patients with PMBCL. The study was published in Military Medicine and can be accessed for further information. [Extracted from the article]

Researchers HWANG, Joonsung and KIM, Jeeeune have submitted a patent application for a pharmaceutical composition aimed at preventing or treating allergic skin diseases or pruritus, particularly focusing on atopic dermatitis. The application highlights the high prevalence of atopic dermatitis globally and the need for more accurate diagnostic methods and appropriate therapeutic solutions, especially for infants and toddlers. The composition includes compounds ABT-751 or TN-16 and offers various formulations for skin application, aiming to address the challenges in diagnosing and treating allergic skin conditions. [Extracted from the article]

A recent study conducted in Taiwan investigated the association between pruritus (itching) and cancer and mortality in patients with dermatomyositis and polymyositis. The study found that pruritus was associated with an increased risk of cancer and a lower risk of all-cause mortality in these patients. The findings suggest that pruritus could be used as a factor for risk stratification and tailored treatment strategies in dermatomyositis and polymyositis. The study recommends comprehensive cancer screening for patients with these conditions, particularly those experiencing pruritus. However, patients without pruritus should still receive vigilant management for potential complications and comorbidities. [Extracted from the article]

A study conducted by researchers at the University of Basel in Switzerland examined the prevalence and patterns of scratch lesions in 124 patients with pruritus (itching). The researchers found that scratch lesions can reflect a patient's perception of itch and underlying disease. The most common types of scratch lesions were erosions/excoriations, followed by erythematous striated lesions and crusts. The study also identified distinct scratch patterns in different diagnoses, which could be used to develop a diagnostic algorithm. However, the researchers noted that larger studies are needed to further support their findings. [Extracted from the article]

A recent report from the University of Modena and Reggio Emilia in Italy discusses the treatment of pruritus, a symptom commonly associated with cholestasis, a condition that affects bile production or excretion. The report highlights the limited current treatment options for cholestatic pruritus and explores potential novel therapies, such as monoclonal antibodies and PPAR agonists. The researchers emphasize the need for more effective and well-tolerated treatments to address the distressing impact of pruritus on patients' quality of life. Despite the challenges, advancements in understanding the underlying mechanisms offer hope for better therapies in the future. [Extracted from the article]

A recent report discusses the role of interleukin 31 (IL-31), a proinflammatory cytokine, in connecting pruritus (itching) and cancer. IL-31 is mainly secreted by Type II helper T cells and can induce itching in mammals. The high expression of IL-31 is associated with advanced stage tumors and the severity of pruritus in cancer patients. While IL-31 has been extensively studied in skin diseases, its precise role in different types of cancer remains unclear. Further research is needed to understand the biology of IL-31 in cancer pathogenesis. [Extracted from the article]

A recent study conducted by researchers at the University of Texas Medical Branch in Galveston has found that pre-existing skin diseases can predict the development of post-burn pruritus (PBP), a condition that negatively impacts the quality of life for burn patients. The study utilized data from electronic health records and compared burn patients with a history of pruritic skin disorders to those without such disorders. The findings showed that patients with pre-existing skin conditions were more likely to develop PBP, with the highest risk occurring one year after the burn injury. The study also identified certain demographic factors, such as gender, race, age, and the size of the burn, that increased the risk of PBP. This research has been peer-reviewed and published in The American Journal of Surgery. [Extracted from the article]

A recent study conducted at Oregon Health & Science University (OHSU) has found that lebrikizumab, a selective interleukin-13 inhibitor, shows significant improvements in multiple dimensions of atopic dermatitis. The study involved two phase 3 trials and found that lebrikizumab resulted in fast and significant improvements in clinical signs, symptoms, and quality of life over a 16-week period in patients with moderate-to-severe atopic dermatitis. The findings suggest that lebrikizumab may be an effective treatment option for individuals with this chronic inflammatory skin disease. [Extracted from the article]

A new report from researchers in Taichung, Taiwan explores the potential role of vitamin D in managing chronic pruritus, a condition that significantly impacts patients' quality of life. The researchers conducted a meta-analysis of randomized controlled trials to assess the effectiveness of vitamin D supplementation in alleviating chronic pruritus. The findings suggest that vitamin D supplementation is associated with a significant reduction in pruritus severity, skin lesion area, and levels of inflammatory cytokines. However, further studies are needed to validate these findings and understand the underlying mechanisms. [Extracted from the article]

A study conducted by investigators from Fudan University in Shanghai, China, examined the efficacy of ceramide-containing cream on skin pruritus in elderly inpatients. The study involved 50 subjects with an average age of 74 years and found that both the ceramide-containing cream and the base cream significantly improved dryness and itching symptoms in elderly individuals. However, the ceramide-containing cream showed more pronounced improvement compared to the base cream. The research concluded that ceramide-containing creams are more effective in alleviating dryness and itching in elderly individuals. [Extracted from the article]

A recent report from the University of Tennessee discusses the diagnosis and management of pruritus ani, a condition that causes itching or burning in the perianal area. The report highlights the lack of quality evidence and published guidelines for diagnosing and treating this condition. It emphasizes the importance of a thorough history and physical examination to rule out secondary causes and suggests a treatment algorithm. The researchers also stress the significance of education on anal hygiene and recommend considering biopsy for patients with refractory pruritus or abnormal exams. For more information, readers can refer to the World Journal of Colorectal Surgery article on this topic. [Extracted from the article]

A recent report discusses research conducted at Kyungpook National University in Sangju, South Korea, on the topic of pruritus, or itching. The study focused on the development of a cream called RaepenolTM, which contains natural compounds and has the potential to promote wound healing and relieve itching. The cream was tested on animal models and showed promising results in terms of wound closure, regeneration of skin, and suppression of itching. The researchers suggest that RaepenolTM cream could be a beneficial option for wound care and itch relief, offering advantages over current ointments. [Extracted from the article]

A recent report from Osaka University in Japan discusses the use of dupilumab, an anti-IL-4Ra antibody, as a therapeutic agent for atopic dermatitis (AD), a chronic eczematous skin disease. The study aimed to identify biomarkers and patient-related factors that could predict the effectiveness of dupilumab treatment. The researchers found that baseline biomarkers such as lactate dehydrogenase (LDH) and periostin, as well as clinical factors like comorbidity of food allergy and duration of severe disease, could be useful indicators for selecting dupilumab as a systemic treatment for AD. The research suggests that these factors can help predict the efficacy of dupilumab. [Extracted from the article]

A recent report from the Hospital for Sick Children and the University of Toronto discusses the limited therapeutic options available for managing cholestasis, a condition that affects the liver and bile ducts. The report highlights the potential of a new class of drugs called ileal bile acid transporter (IBAT) inhibitors in treating cholestatic liver diseases, particularly in pediatric patients. These drugs have been shown to reduce serum bile acid levels and alleviate pruritus (itching) with minimal side effects. The report suggests that IBAT inhibitors may become a viable alternative to invasive surgical procedures like liver transplantation for progressive cases of cholestasis. Ongoing clinical trials are expected to expand the indications for IBAT inhibitors in the future. [Extracted from the article]

A systematic review conducted by researchers at San Bortolo Hospital in Vicenza, Italy, examined the effects of different dialysis modalities on chronic kidney disease-associated pruritus (CKD-aP). The review included 8 randomized controlled trials, 3 observational studies, and 6 prospective clinical trials. The researchers found that, apart from hemadsorption, the current evidence for dialytic treatment of CKD-aP is weak. They concluded that more high-quality studies are needed to confirm the long-term benefits of blood purification therapies in treating CKD-aP. [Extracted from the article]

A recent study conducted at the Postgraduate Institute of Medical Education and Research in Chandigarh, India, has examined the effects of anabolic androgenic steroids (AASs) on the liver. The study found that AASs can cause various forms of liver injury, including a rare cholestatic syndrome with bland histology. In cases where conventional pharmacotherapeutic measures fail to alleviate symptoms, plasmapheresis may provide long-lasting relief. The study highlights the need for caution and awareness regarding the misuse of AASs, particularly among amateur athletes seeking cosmetic and performance-enhancing effects. [Extracted from the article]

A recent study conducted by researchers at Korea University Medical Center in Seoul, South Korea, has found that subcutaneous injections of botulinum toxin type A (BTX-A) may be an effective treatment for postherpetic neuralgia (PHN) and postherpetic pruritus (PHP) that persist for more than four years and do not respond to conventional treatments. The study involved a 71-year-old man who had been experiencing itching and pain for three years following a shingles diagnosis. After receiving the BTX-A injection, the patient reported a significant decrease in pain and itching, although he did experience temporary side effects such as drooping eyelids and a shifted eyeball. The researchers concluded that while BTX-A injections may be a viable alternative for chronic and refractory neurological diseases like PHN and PHP, caution should be exercised to minimize the risk of side effects. [Extracted from the article]

A recent study conducted by researchers at the Medical College of Rzeszow University in Poland focused on pruritus, or itching, in patients with lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA). The study analyzed 61 patients with scarring alopecia and found that itching of the scalp was a common symptom, occurring in 73.8% of the patients. The severity of pruritus was found to be related to certain dermoscopic features such as perifollicular scaling, hair diameter diversity, and white halo. The researchers concluded that a better understanding of pruritic features could aid in the development of effective therapeutic strategies for LPP and FFA. [Extracted from the article]

A clinical trial, NCT06574204, is currently being conducted to examine the pain and itching caused by allergic contact dermatitis resulting from macrolide antibiotics. The trial aims to enroll 30 healthy individuals who will undergo a single skin test with either erythromycin or azithromycin. The study will assess the occurrence of hypersensitivity reactions and local skin reactions through observation and participant questionnaires. The goal of the trial is to enhance the understanding of side effects and improve the clinical application of macrolide antibiotics. The document provides information about the study, including eligibility criteria and contact information for those interested in participating. [Extracted from the article]

A recent report from the University of Miami discusses the findings of two phase 3 trials on the use of dupilumab in patients with prurigo nodularis, a skin condition characterized by severe itching and skin lesions. The trials showed that dupilumab was effective in improving itch, skin clarity, and overall quality of life in patients with prurigo nodularis. The treatment benefits were consistent across different demographic groups, and the safety profile of dupilumab was generally acceptable. However, it is important to note that the data was limited to a 24-week period. Overall, the findings confirm the positive effects of dupilumab in treating prurigo nodularis. [Extracted from the article]

A recent study conducted at Shaheed Beheshti University of Medical Sciences in Tehran, Iran, aimed to assess the effectiveness of using topical tranexamic acid with micro-needling compared to micro-needling alone in treating macular amyloidosis, a form of primary localized cutaneous amyloidosis. The study involved twenty female participants with bilaterally located macular amyloidosis on their trunk or upper extremities. Both groups showed improvement in pigmentation and rippling pattern, and there was no significant difference in patient satisfaction between the two groups. However, the topical application of tranexamic acid did not lead to additional improvement. The study concluded that micro-needling is a suitable modality for decreasing pruritus and pigmentation in macular amyloidosis. [Extracted from the article]

A recent study explored the potential causal relationship between Helicobacter pylori (H. pylori) infection and various skin disorders. Using Mendelian randomization analysis, the researchers found a positive causal relationship between H. pylori catalase antibody levels and alopecia areata (AA), as well as a positive causal relationship between H. pylori UreA antibody levels and pruritus. These findings suggest that H. pylori infection may be a risk factor for AA and pruritus, which could have implications for the prevention and treatment of these skin disorders. It is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers at Universitas Islam Indonesia aimed to analyze the association between house dust mite density and pruritus (chronic itch) levels among elderly residents. The study found that while itch scale in the elderly was not related to house dust mite density, it was correlated with the habit of cleaning the mattress. The dominant mite species found in the elderly's rooms were Dermatophagoides sp. This research provides valuable insights into the risk factors and prevention strategies for pruritus in the elderly population. [Extracted from the article]

The article discusses interim results from a phase 3b open-label study (ADmirable) that evaluates the efficacy and safety of lebrikizumab in treating moderate-to-severe atopic dermatitis in patients with skin of color. Topics include the study's focus on baseline demographics and clinical characteristics, the efficacy outcomes measured at Week 16, and the absence of serious adverse events during the trial.

The article reports on research from Oregon Health & Science University (OHSU) evaluating the effectiveness of tapinarof cream 1 percent for atopic dermatitis in two phase 3 trials. Topics include rapid itch relief onset, sustained efficacy, and patient tolerance in both adults and children as young as 2 years.

The article from the University of Miami Miller School of Medicine explores the impact of pruritus on patient fatigue, focusing on a case-control study that reveals a significant correlation between chronic pruritus and increased fatigue levels. Topics discussed include the association between pruritus and fatigue in atopic dermatitis, the use of the AoU database for the study, and the statistical methods used to analyze the data.

The article offers information on the identification of a novel biomarker signature in chronic pruritus of unknown origin (CPUO) through plasma metabolomic profiling. Topics discussed include the significant differences in blood metabolites between CPUO patients and controls; the correlation of these metabolites with itch severity; and the downregulation of specific metabolic pathways related to CPUO.

A recent study conducted by the University Medical Center Groningen in the Netherlands examined the long-term effectiveness and reasons for discontinuation of dupilumab, a treatment for atopic dermatitis (AD). The study analyzed data from 1,286 patients with AD who were treated with dupilumab for up to 5 years. The results showed that most patients maintained controlled AD with low levels of symptoms, and two-thirds of patients were able to taper their dosage to every 3 or 4 weeks. However, 23.8% of patients discontinued the treatment due to adverse events or ineffectiveness. The study provides valuable insights into the long-term use of dupilumab for AD. [Extracted from the article]

A report from researchers at the University of Hong Kong discusses the role of Mas-related G Protein-coupled Receptor Member X2 (MRGPRX2) in pruritus (itching) and skin diseases. The researchers highlight the prevalence and burden of inflammatory skin conditions such as chronic spontaneous urticaria, atopic dermatitis, psoriasis, and rosacea. They emphasize the multifactorial nature of these conditions and the involvement of genetic, immune, and environmental factors. The study reviews the pathogenic role of MRGPRX2 and its potential as a novel therapeutic target, emphasizing the need for new drug targets and treatment options for these chronic inflammatory skin conditions. [Extracted from the article]

A recent study conducted at the University of Muenster in Germany has examined the role of interleukins in atopic dermatitis (AD) and chronic nodular prurigo (CNPG). The study found that IL-4 and IL-13, along with their corresponding receptors, play a crucial role in the pathogenesis of pruritus in both conditions. However, the expression of IL-13RA2, a decoy receptor, was significantly increased in AD compared to CNPG and healthy controls. These findings provide insights into the underlying mechanisms of pruritus and offer potential avenues for therapeutic intervention. [Extracted from the article]

A recent study conducted at Cincinnati Children's Hospital explored the use of aprepitant, a neurokinin-1 receptor antagonist, in treating refractory pruritus (itching) in patients with epidermolysis bullosa (EB) and atopic dermatitis (AD). The study included 37 patients, ranging in age from 10 months to 37 years, with 58% of EB patients and 85% of AD patients reporting that aprepitant effectively reduced their pruritus. The study suggests that aprepitant shows promise in controlling refractory pruritus in pediatric EB and AD patients and warrants further investigation. [Extracted from the article]

A recent study conducted by researchers at Wroclaw Medical University in Poland aimed to assess the serum concentration of interleukin-5 receptor (IL-5R) in relation to disease activity and pruritus intensity in adult patients with atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). The study included 45 participants, with 15 patients in each group (AD, CSU, and healthy controls). The results showed that the IL-5R concentration was significantly higher in patients with CSU compared to patients with AD and the control group. However, there was no correlation between IL-5R levels and disease severity or pruritus intensity. The researchers concluded that while IL-5R may play a functional role in the pathogenesis of these diseases, it may not be fully useful in reflecting symptom severity. Further studies with larger patient cohorts are needed to confirm these findings. [Extracted from the article]

A recent study conducted by Charite - University Medicine Berlin examined the characteristics of pruritus (itching) in primary cutaneous T-cell lymphoma (CTCL) patients. The researchers found that pruritus was prevalent and severe in CTCL patients, leading to significant impairment in quality of life, sleep, and psychological distress. Elevated levels of certain mediators, such as IL-31 and tryptase, were found in CTCL patients with pruritus, suggesting that these could be potential therapeutic targets for managing itching in CTCL patients. The study highlights the need for appropriate therapeutic management of pruritus in CTCL patients. [Extracted from the article]

This document provides information about a clinical trial study evaluating the efficacy and safety of a drug called Povorcitinib in participants with a skin condition called prurigo nodularis. The study aims to assess the effect of Povorcitinib on itch and skin lesions. The trial is in the recruitment phase and plans to enroll 330 participants. The study is being conducted by Incyte Corporation. [Extracted from the article]

A study conducted at the University of Maryland has found that abrocitinib, a Janus kinase 1 inhibitor, may be an effective and well-tolerated treatment for prurigo nodularis (PN) and chronic pruritus of unknown origin (CPUO). The study involved 20 adult patients with moderate to severe PN or CPUO who were treated with 200 mg of abrocitinib once daily for 12 weeks. The results showed a significant reduction in pruritus scores and improvement in quality of life for both PN and CPUO patients. However, further randomized, double-blind, placebo-controlled trials are needed to confirm these findings. [Extracted from the article]

A clinical trial is being conducted in China to compare the effectiveness and safety of two treatments for refractory nodular prurigo, a chronic inflammatory skin disease. The trial will enroll 60 patients and will involve intralesional injections of either 5-fluorouracil alone or 5-fluorouracil plus triamcinolone acetonide. Patients will receive the medication once every 4 weeks for 12 weeks, with follow-up visits scheduled throughout the study. The primary outcome measures include the clearance rate and improvement in the NRS score. The trial is not yet recruiting and is expected to be completed by August 31, 2026. The document also outlines the inclusion and exclusion criteria for the trial, including age restrictions, duration of the condition, previous treatments, and medical history. The trial is open to all genders and the age range is 18 to 70 years. Administrative information, such as the study ID number and data sharing plans, is also provided. [Extracted from the article]

This document provides information about a clinical trial for a drug called lebrikizumab, which is being tested as a treatment for atopic dermatitis (AD), a chronic skin condition. The trial is currently recruiting participants and aims to enroll 520 adults and adolescents with AD. The study will assess the effectiveness of lebrikizumab in reducing symptoms such as itching and sleep loss. The trial has specific eligibility criteria, including a history of inadequate response to topical medications and a minimum duration of AD symptoms. The study is being conducted in Spain and is expected to be completed by April 2026. [Extracted from the article]

A recent study conducted by researchers at Niigata University Graduate School of Medical and Dental Sciences in Japan has found that difelikefalin, a drug that targets kappa opioid receptors, is effective in treating moderate-to-severe pruritus (itching) in hemodialysis patients. The study, which lasted for 52 weeks, showed that difelikefalin improved itching and itch-related quality of life in patients who had not responded well to conventional medications. The drug was also found to be safe and well-tolerated. The findings of this study provide valuable insights into the long-term efficacy and safety of difelikefalin for the treatment of pruritus in Japanese hemodialysis patients. [Extracted from the article]

A recent study conducted by researchers at Northwell Health in Great Neck, New York, examined the relationship between pruritus severity (itching) and serum phosphate levels in patients with chronic kidney disease (CKD). The study utilized data from Phase 3 difelikefalin studies and found that there was no correlation between pruritus severity and serum phosphate levels. Additionally, the study found that difelikefalin, an antipruritic agent, improved itch in patients with CKD regardless of their baseline serum phosphate levels. This research provides valuable insights into the treatment of pruritus in CKD patients undergoing hemodialysis. [Extracted from the article]

A study conducted in Sichuan, China, explores the occurrence of pruritus, or itching, as an immune-related adverse event in patients receiving immune checkpoint inhibitors (ICIs) for cancer treatment. The study focuses on a case of refractory pruritus in a patient with gallbladder neuroendocrine carcinoma who experienced severe itching after using the drug sintilimab. The researchers discuss the management of this case and highlight the importance of collaboration between clinical pharmacists and clinicians in treating difficult cases of refractory pruritus. This case report provides valuable insights for healthcare professionals dealing with similar situations. [Extracted from the article]

A clinical trial, NCT06504160, is currently underway to assess the safety and effectiveness of a topical gel called ShA9 in treating atopic dermatitis (AD). The trial is specifically targeting adults and adolescents with AD who have tested positive for S. aureus colonization. The primary objective of the study is to determine if ShA9 can extend the period of AD control for 12 weeks after initial treatment with topical corticosteroids. The trial is expected to be completed by March 2026. The eligibility criteria for participants include specific percentages of body surface area affected by AD, a certain score on the Investigator's Global Assessment, and a positive skin swab test for S. aureus. Exclusion criteria include allergies to certain products and medical conditions that may interfere with the study. The study is being conducted in the United States. [Extracted from the article]

This document provides information about a clinical trial conducted in China on the treatment of senile pruritus, or itching in elderly individuals. The trial is a randomized, sham-controlled clinical trial, with participants being assigned to either an acupuncture group or a sham acupuncture group. The treatment will be administered by licensed practitioners and will involve acupuncture or sham acupuncture three times a week for six weeks. The trial is currently recruiting participants, and the completion date is projected to be February 28, 2026. The document also includes eligibility criteria for participants and contact information for the primary investigator. [Extracted from the article]

A recent report from Cincinnati Children's Hospital Medical Center provides new information on intrahepatic cholestasis, a group of disorders that disrupt bile formation and cause cholestasis and pruritus. The study aimed to evaluate the efficacy and safety of maralixibat, an ileal bile acid transporter inhibitor, in participants with all types of progressive familial intrahepatic cholestasis (PFIC). The trial involved 93 participants aged 1-17 years and found that maralixibat significantly improved pruritus and serum bile acids compared to placebo. The researchers concluded that maralixibat represents a non-surgical, pharmacological option to improve the standard of care for patients with PFIC. [Extracted from the article]

A recent study conducted at George Emil Palade University of Medicine in Romania aimed to assess the prevalence and characteristics of pruritus (itching) in patients with psoriasis. The study found that 70.55% of patients reported itch, which was associated with higher psoriasis severity scores. The itch was most commonly described as a crawling sensation, located in the affected skin, and aggravated by stress and temperature changes. Emollients were the preferred treatment for itch relief, while biologics showed a protective effect against itch development. Factors such as age, BMI, and psoriasis severity were indicators of itch presence, while female gender, high psoriasis severity, and frequent itch episodes indicated more intense pruritus. The study highlights the importance of understanding itch and its clinical features to guide physicians in selecting the most effective treatment options for patients. [Extracted from the article]

A recent study conducted at University Hospital Mainz in Germany explored the presence of pruritus (itching) in patients with peripheral neuropathy (PNP) and its relationship with anxiety. The study involved 191 patients with PNP and 57 control subjects, who underwent various tests and questionnaires to assess their symptoms and quality of life. The findings revealed that patients with pruritus and pain experienced higher levels of anxiety, depression, and reduced quality of life compared to control subjects. The study also identified sensory and structural abnormalities associated with neuropathic pruritus. This research provides valuable insights into the impact of neuropathic pruritus on patients with PNP and highlights the need for further investigation in this area. [Extracted from the article]